Tissue and circulating biomarkers in advanced melanoma patients receiving dabrafenib and trametinib

We investigated tumor microenvironment (TME) immunophenotype, tissue genomic features, ctDNA, and exosomes within the TWIN study, a prospective observational study of first-line dabrafenib and trametinib in BRAFV600 mutated MM patients treated in Italian Melanoma Intergroup centers. Between November 2017 to May 2019, 201 patients were enrolled; 160 had at least one valid baseline sample and constituted the biomarker analysis population. Among them, mean age was 61.9, 62.5% were male, ECOG performance status was 0 in 73.8%, TNM stage was predominantly M1c (35.6%) or M1d (25.6%), LDH was >ULN in 36.3%, and 48.1% had ≥3 metastatic sites.